Adverse events with bioresorbable vascular scaffolds in routine percutaneous coronary interventions: “coup de théatre” or unfinished play?

Bioresorbable scaffolds are percutaneous coronary prostheses designed to ensure transient support of the dilated vessel and dissolution into inert breakdown products overtime (1). By leaving the coronary artery without a permanent metallic implant, bioresorbable scaffolds have been developed to absolve three main commitments: improve long-term vessel healing and remodelling, restore vasomotor function of the treated segment, and reduce the burden of angina symptoms in comparison with conventional drug-eluting stent (DES) platforms